Frankfurt/Main – DETAX, a specialist in polymer materials for medical use and a leading provider of bio-compatible silicones and light-curing 3D resins for dental and audio medical applications, has chosen a management buy-out as a succession solution. A consortium of investors consisting of funds managed by ECM Equity Capital Management GmbH, PINOVA Capital GmbH and Gilde Healthcare has taken a majority stake in the DETAX Group as part of the MBO. The two long-standing CEOs, Ursula Juretzki-Mangold and Ralf König, have also acquired an equity interest in the company. After more than 65 years, the transition from the Regneri family to the new owners has now been completed. Together with the investor consortium, the company intends to continue its successful growth strategy. The transaction is currently awaiting approval from the competition authorities. The financial details of the transaction were not disclosed.
A CMS team headed by lead partner Dr Hendrik Hirsch advised the Regneri family as the sellers on all legal aspects of the deal.
CMS Germany
Dr Hendrik Hirsch, Lead Partner, Frankfurt/Main
Maxine Notstain, Senior Associate, Frankfurt/Main
Maximilian Stark, Associate, Frankfurt/Main, all Corporate/M&A
Dr Roland Wiring, Partner, Hamburg
Dr Elisa Fontaine, Senior Associate, Hamburg, both Regulatory, Life Sciences & Healthcare
Dr Malte Grützmacher, Partner, Hamburg
Martin Kilgus, Counsel, Stuttgart
Christian Schultz, Associate, Hamburg, all TMC
Dr Tobias Polloczek, Partner, Frankfurt/Main
Dr Boris Alles, Counsel, Frankfurt/Main
Shae Lynn Washington, Consultant, Berlin, all Labor, Employment & Pensions
Dr Dirk Smielick, Counsel, Cologne, Intellectual Property
Dr Franz Maurer, Senior Associate, Frankfurt/Main
Juliana Kettel, Associate, Frankfurt/Main, both Real Estate & Public
Stefan Lehr, Partner, Frankfurt/Main, Competition & EU
Press Contact
presse@cms-hs.com
